Biotechnology

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

January 12, 2026 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced the addition of Dominion Medical Associates, Inc., a Richmond, Virginia-based clinical research site within Lightship's site network, to the Company's Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in...

Read more

ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

January 12, 2026 8:30 AM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced preliminary unaudited revenue growth for its fourth quarter of 2025. These preliminary unaudited financial results are management's estimates, are subject to revision in the course of completing annual audit processes, and do not represent a comprehensive statement of...

Read more

PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference

January 9, 2026 12:35 PM

PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic...

Read more

Microbix Updates Investor Presentation on its Website

January 9, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has updated the investor presentation on its corporate website in response to comments of staff of the Ontario Securities Commission (OSC & OSC Staff) in relation to its usage of earnings before interest, taxes, depreciation, and amortization (EBITDA), a measure of financial results not formally-defined by...

Read more

Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026

January 9, 2026 3:00 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that new data from its Phase 1b/2 OPTIMIZE-1 study evaluating mitazalimab in combination with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) will be presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA, taking...

Read more

LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform

January 8, 2026 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790) (WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered into a services agreement ("R&D Agreement") with Neuland Laboratories Limited ("Neuland Labs"), a global contract development and manufacturing organization (CDMO), under which Neuland Labs is to provider R&D services to test and advance novel peptide formulations that underpin LIR's transdermal...

Read more

Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy

January 8, 2026 8:55 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported audited financial results for the fiscal year ended August 31, 2025 ("FY2025") and provided an update on operational progress achieved since the Company's leadership transition and Board renewal beginning in late 2024. Dr. Frederick D. Sancilio, Chairman and...

Read more

AbTherx and Red Queen Bio Partner on Therapeutic Antibody Discovery

January 8, 2026 6:00 AM

AbTherx today announced a therapeutic antibody discovery and development partnership with Red Queen Bio, combining AbTherx's Atlas™ Full Human Diversity Transgenic Mouse platform with Red Queen Bio's vaccination and AI-driven antibody development pipeline. The collaboration is focused on generating antibodies against targets selected by Red Queen Bio. The partners have already generated initial in vivo antibody data under the collaboration....

Read more

NAYA Therapeutics Announces European Research & Manufacturing Hub At Paris-Saclay Cancer Cluster (PSCC)

January 7, 2026 9:15 AM

NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of Astatine-211 (²¹¹At) targeted alpha therapies and immune redirecting multispecific antibodies, today announced that it has been selected to join the Paris-Saclay Cancer Cluster (PSCC)'s BOOST acceleration program and will establish its European research & manufacturing hub at Campus Grand Parc,...

Read more

Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States

January 7, 2026 7:45 AM

Cytora Therapeutics Ltd. (Cytora), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO); and Zeo ScientifiX, Inc. (Zeo), a Florida-based clinical-stage biopharmaceutical company specializing in research, clinical trials, manufacturing and the commercialization, and...

Read more

Vicore Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026 2:15 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference: Location: Westin St. Francis, San Francisco, USA Format: Presentation and 1×1 meetings Presentation Date and Time: Thursday, January 15 at 9:00 AM PST Webcast: Link Participants: Ahmed...

Read more

Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation

January 6, 2026 8:21 AM

Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced publication of long-term follow-up results from its successfully concluded Phase II clinical trial of GelrinC® in the peer-reviewed journal Cartilage. The study, led by Prof. Siegfried Trattnig of Vienna University and colleagues, reports strong radiologic evidence of...

Read more

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

January 6, 2026 8:00 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that its Board of Directors has approved a change in the Company's fiscal year end from March 31 to December 31, effective December 31, 2025. "This is a straightforward but important step in strengthening how we...

Read more

Empyrean Medical Systems Secures Strategic Financing from Hamilton Reserve Bank, Advances Radiation Oncology Innovation

January 6, 2026 8:00 AM

Empyrean Medical Systems, Inc. (www.empyreanmed.com), a leading Florida-based radiation oncology company, and Hamilton Reserve Bank ("HRB" www.hrbank.com), the largest global bank headquartered in the Caribbean with more than USD 4.2 billion in assets, have completed a strategic investment agreement to support Empyrean's mission to disrupt radiation oncology and launch first-in-class technologies to market in 2026. The Bank serves clients from...

Read more

Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

January 6, 2026 6:00 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported audited financial results for the fiscal year ended August 31, 2025 ("FY2025") and provided an update on operational progress achieved since the Company's leadership transition and Board renewal beginning in late 2024. Dr. Frederick D. Sancilio, Chairman and CEO of...

Read more

Moolec Science Announces Effectiveness of Share Consolidation

January 5, 2026 9:00 PM

Moolec Science SA ("Moolec" or the "Company") today announced that, in accordance with the resolutions passed at the extraordinary general meeting of shareholders held on December 16, 2025, and the resolutions adopted by the Company's board of directors on December 19, 2025, the Company has consummated, effective as of January 5, 2026, the previously announced share consolidation at a ratio of 15-for-1, so that all shareholders holding every 15...

Read more

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

January 5, 2026 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that it has entered into a Subscription Agreement (the "2025 SA") with a group of investors for the purchase and sale of an aggregate of 779,997 shares of common stock in a registered direct offering, at a purchase price of $0.30 per...

Read more

BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer

January 5, 2026 1:45 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced encouraging interim results from its ongoing Phase 2a signal-seeking study evaluating BI-1808, a novel immuno-oncology candidate, in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy...

Read more

Moolec Receives Staff Determination Letter and Provides Update on Nasdaq Listing Compliance Status

December 31, 2025 6:00 PM

Moolec Science SA ("Moolec" or the "Company") received an additional determination letter (the "Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company does not currently meet the minimum stockholders' equity requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1). As previously disclosed in the Company's Form 20-F for the year ended June 30, 2025, management expects to...

Read more

Moolec Science SA Announces the Implementation of a Share Consolidation of Its Ordinary Shares, Par Value U.S.$0.10 Per Share (the "Shares")

December 31, 2025 9:00 AM

Moolec Science SA (NASDAQ:MLEC) "The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that its board of directors (the "Board") has determined the effective date and the final ratio for the previously approved share consolidation of Moolec's ordinary shares of par value of US$0.10 each (the "Share Consolidation"). The Share Consolidation will become...

Read more